Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | SMARCA4 loss |
| Therapy | Tozasertib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| SMARCA4 loss | lung non-small cell carcinoma | sensitive | Tozasertib | Preclinical - Cell culture | Actionable | In a preclinical study, non-small cell lung cancer cell lines with SMARCA4 loss demonstrated increased sensitivity to Tozasertib (VX-680), compared to cell lines expressing wild-type SMARCA4, in culture (Cancer Res July 15 2016 (76) (14 Supplement) LB-318). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract LB-318: SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A-targeted therapies in non-small cell lung cancers (NSCLCs) | Full reference... |